Advances in modulating thermosensory TRP channels

被引:102
作者
Ferrer-Montiel, Antonio [1 ]
Fernandez-Carvajal, Asia [1 ]
Planells-Cases, Rosa [1 ]
Fernandez-Ballester, Gregorio [1 ]
Manuel Gonzalez-Ros, Jose [1 ]
Messeguer, Angel [2 ]
Gonzalez-Muniz, Rosario [3 ]
机构
[1] Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante, Spain
[2] CSIC, Inst Quim Avanzada, Barcelona, Spain
[3] CSIC, Inst Quim Med, E-28006 Madrid, Spain
关键词
cancer; inflammation; ion channel; nociception; pain; sensory; POTENTIAL VANILLOID-1 ANTAGONISTS; INDUCED NEUROGENIC INFLAMMATION; CAPSAICIN-RECEPTOR HOMOLOG; CATION CHANNEL; SENSORY NEURONS; ION-CHANNEL; NEUROPATHIC PAIN; PROSTATE-CANCER; NERVE INJURY; SPINAL-CORD;
D O I
10.1517/13543776.2012.711320
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
Introduction: Thermosensory channels are a subfamily of the transient receptor potential (TRP) channel family that are activated by changes in the environmental temperature. These channels, known as thermoTRPs, cover the entire spectrum of temperatures, from noxious cold (< 15 degrees C) to injurious heat (> 42 degrees C). In addition, dysfunction of these channels contributes to the thermal hypersensitivity that accompanies painful conditions. Moreover, because of their wide tissue and cellular distribution, thermoTRPs are also involved in the pathophysiology of several diseases, from inflammation to cancer. Areas covered: Although the number of thermoTRPs is increasing with the identification of novel members such as TRPM3, we will cover the recent advances in the pharmacology of the classical thermosensory channels, namely TRPV1, TRPV2, TRPV3, TRPV4, TRPM8 and TRPA1. This review will focus on the therapeutic progress carried out for all these channels and will highlight the tenet that TRPV1, TRPM8 and TRPA1 are the most exploited channels, and that the interest on TRPV3 and TRPV4 is growing with the first TRPV3 antagonist that moves into Phase-II clinical trials. In contrast, the pharmacology of TRPV2 is yet in its infancy. Expert opinion: Despite the tremendous academic and industrial investment to develop therapeutic modulators of thermoTRPs, it apparently seems that we are still far from the first successful product, although hope is maintained high for all compounds currently in clinical trials. A major concern has been the appearance of side effects. A better knowledge of the thermosensory protein networks (signal-plexes), along with the application of system biology approaches may provide novel strategies to modulate thermoTRPs activity with improved therapeutic index. A case in point is TRPV1, where acting on interacting proteins is providing new therapeutic opportunities.
引用
收藏
页码:999 / 1017
页数:19
相关论文
共 172 条
[1]
Abbott Laboratories, 2009, Patent No. [WO089082, 089082]
[2]
Abbott Laboratories, 2009, Patent No. [WO089083, 089083]
[3]
Abbott Laboratories, 2012, Patent No. [WO019315, 019315, WO, 019315 [P]]
[4]
The cell and molecular basis of mechanical, cold, and inflammatory pain [J].
Abrahamsen, Bjarke ;
Zhao, Jing ;
Asante, Curtis O. ;
Cendan, Cruz Miguel ;
Marsh, Steve ;
Martinez-Barbera, Juan Pedro ;
Nassar, Mohammed A. ;
Dickenson, Anthony H. ;
Wood, John N. .
SCIENCE, 2008, 321 (5889) :702-705
[5]
A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators [J].
Alessandri-Haber, N ;
Dina, OA ;
Joseph, EK ;
Reichling, D ;
Levine, JD .
JOURNAL OF NEUROSCIENCE, 2006, 26 (14) :3864-3874
[6]
Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier [J].
Alvarez, Diego F. ;
King, Judy A. ;
Weber, David ;
Addison, Emile ;
Liedtke, Wolfgang ;
Townsley, Mary I. .
CIRCULATION RESEARCH, 2006, 99 (09) :988-995
[7]
Amgen I, 2009, Patent No. [WO073203, 073203]
[8]
Amgen I, 2009, Patent No. [WO038812, 038812]
[9]
Cigarette smoke-induced neurogenic inflammation is mediated by α,β-unsaturated aldehydes and the TRPA1 receptor in rodents [J].
Andre, Eunice ;
Campi, Barbara ;
Materazzi, Serena ;
Trevisani, Marcello ;
Amadesi, Silvia ;
Massi, Daniela ;
Creminon, Christophe ;
Vaksman, Natalya ;
Nassini, Romina ;
Civelli, Maurizio ;
Baraldi, Pier Giovanni ;
Poole, Daniel P. ;
Bunnett, Nigel W. ;
Geppetti, Pierangelo ;
Patacchini, Riccardo .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (07) :2574-2582
[10]
[Anonymous], 2007, Biosciences H Compounds for modulating TRPV3 function, Patent No. [WO2007056124, 056124]